Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Fanconi Anemia, Complementation Group D1 1

Interventions

Cyclophosphamide 93fludarabine phosphate 86Busulfan 63Cyclosporine 57Peripheral Blood Stem Cell Transplantation 54Mycophenolic Acid 54Whole-Body Irradiation 53Epoetin Alfa 53Antilymphocyte Serum 43fludarabine 42Filgrastim 41Cytarabine 41Tacrolimus 39Melphalan 38Darbepoetin alfa 38Methotrexate 34Radiotherapy 32Cord Blood Stem Cell Transplantation 28Granulocyte Colony-Stimulating Factor 23Methylprednisolone 21Etoposide 21apixaban 18eltrombopag 16Thiotepa 16Dalteparin 16ferric carboxymaltose 14Daunorubicin 14Azacitidine 14Alemtuzumab 14thymoglobulin 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × ABT-767 × Classical hematology × Clear all
NCT01339650 2018-01-02

Study of ABT-767 in Subjects With Breast Cancer 1 and Breast Cancer 2 (BRCA 1 and BRCA 2) Mutations and Solid Tumors or High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

AbbVie

Phase 1 Completed
93 enrolled
Classical hematology

Fanconi Anemia, Complementation Group D1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡